Levi & Korsinsky notifies investors that it has commenced an investigation into Oculis Holding AG (NASDAQ: OCS) concerning potential violations of the federal securities laws.
Multiple SEC filings made prior to the stock collapse continued to present the OCS-01 DME program as progressing toward regulatory approval. A prospectus supplement filed on October 31, 2025 stated that topline results from the DIAMOND trials were "expected in the second quarter of 2026,” with a subsequent New Drug Applications (NDAs) submission to the U.S. FDA to begin in Q4 2026. A 6-K filed on October 6, 2025 described Oculis as being "in a strong position with multiple pivotal studies, targeting multi-billion-dollar markets" in connection with the DME program. The Company ultimately disclosed that the pivotal DIAMOND trials failed and announced it would abandon the FDA filing for DME entirely. Oculis stock fell over 23% on the announcement.
If you suffered a loss on your Oculis Holding AG securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





